造血干细胞MYB增强剂对于T细胞白血病发生过程中是必不可少的,并且在T细胞白血病发生过程中经常被放大
Carea Mullin1, Karena Lin2, Elizabeth Choe1
1Division of Hematology-Oncology, Department of Internal Medicine, and.
The Journal of clinical investigation
|October 23, 2025
概括
研究人员发现了一种新型干细胞增强剂H-Me,对T细胞急性淋巴细胞白血病 (T-ALL) 的发展至关重要. 针对这一元素为T-ALL治疗提供了一个有希望的新策略,克服了与以前治疗相关的毒性.
科学领域:
- 血液学 血液学 血液学
- 癌症生物学 癌症生物学
- 分子瘤学分子瘤学
背景情况:
- 紧急需要针对性治疗的T细胞急性淋巴细胞白血病 (T-ALL).
- 潘诺奇抑制剂显示有效性,但导致剂量限制性毒性.
- ETS1是一个关键的转录因子,在T-ALL中联合结合了Notch调节的元素.
研究的目的:
- 确定推动T-ALL的关键监管要素.
- 调查ETS1依赖增强剂在T-ALL病变发生中的作用.
- 发现T-ALL的新型治疗点.
主要方法:
- 全基因组的CRISPRi屏幕用于识别关键的ETS1依赖的监管元素.
- 对增强剂-促进剂相互作用 (AHI1 内子和 MYB 促进剂) 的分析.
- 在T-ALL和造血干细胞自我更新的小鼠模型中的验证.
主要成果:
- 确定了造血干细胞MYB增强剂 (H-Me) 作为排名第一的元素.
- H-Me促进了造血干细胞的自我更新和T-ALL白血病的产生.
- 在约8.5%的T-ALL患者中,H-Me与MYB被放大,并在白血病发生过程中获得.
- ETS1招募cBAF到H-Me,提高染色质的可访问性和MYB的激活.
结论:
- H-Me是一种可向的干细胞元素,在T-ALL.中被采用.
- 针对H-Me或其相关因子 (ETS1,cBAF) 为T-ALL.提供了一个新的治疗策略.
- 这一发现提供了一种替代Pan-Notch抑制剂的替代品,可能降低毒性.
更多相关视频
相关概念视频
01:19Multipotency of Hematopoietic Stem Cells
3.8K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.8K
01:06Induced Pluripotent Stem Cells
5.4K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
5.4K
01:01Regulation of Hematopoietic Stem Cells
3.9K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.9K
01:15Differentiation of Common Myeloid Progenitor Cells
3.9K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.9K
01:21Lineage Commitment
4.1K
Commitment is the process whereby stem cells:
4.1K
01:21Hematopoiesis
8.7K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
8.7K